Drug reference
imdevimab
recombinant human mAb · SARS-CoV-2 monoclonal antibody
recombinant human mAbSARS-CoV-2 monoclonal antibody
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Imdevimab is a recombinant human monoclonal antibody that binds to nonoverlapping epitopes of the spike protein receptor binding domain (RBD) as part of a combination with casirivimab.
Indications
treatment of mild to moderate COVID-19 in nonhospitalized patients with laboratory-confirmed SARS-CoV-2 infection who are at high risk for progressing to severe disease and/or hospitalization (as part of a combination with casirivimab)
Contraindications
- SARS-CoV-2 antigenic variants of concern emerged that evaded its action, leading to EUA revocation
Related guidelines
Other recombinant human mAb drugs
Ask House about imdevimab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team